Iopofosine

Small moleculeexperimental

Clinical trial activity

5 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2016 (NCT02952508)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiodepletion

    radiodepletion

Chemistry & pharmacology

Loading structure…

SMILES

C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCc1ccc(I)cc1
Mol. weight
637.62 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Payload
131-iodine

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • clr 131

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07311993Phase 1Dec 5, 2025Cellectar, Inc
NCT05610891Phase 1Nov 30, 2022Balance Therapeutics, Cellectar, Inc, National Cancer Institute (NCI)
NCT04105543Phase 1Oct 31, 2019Cellectar, Inc, National Institute of Dental and Craniofacial Research (NIDCR), University of Wisconsin
NCT03478462Phase 1Jul 31, 2018Cellectar, Inc, University of Wisconsin
NCT02952508Phase 2Dec 1, 2016Cellectar, Inc
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cellectar, IncFor profit5422016
University of WisconsinAcademic/Hospital2112018
Balance TherapeuticsFor profit1012022
National Cancer Institute (NCI)Government1012022
National Institute of Dental and Craniofacial Research (NIDCR)Government1012019
5 organizations
Page 1 / 1